STAT+: Pharmalittle: Pfizer CEO rallies employees to fight drug-price negotiations; Glaxo head pressured by another activist fund
Rise and shine, everyone, another busy day is on the way. We can tell because assorted short people are messaging us with questions, the official mascot is bounding about the campus grounds in search of varmints, and the to-do list is growing quickly. So this calls for action — firing up the coffee kettle to brew some cups of stimulation. Our choice today is pumpkin spice. Please feel free to join us. Remember, no prescription is required, so no rebate must be paid. Meanwhile, here are some tidbits. Have a smashing day and please do keep in touch. …
GlaxoSmithKline (GSK) chief executive officer Emma Walmsley has come under pressure from a second activist hedge fund, Bluebell Capital Partners, which has taken a stake worth about $14 million in the drug maker to push for change at the top, including demanding that she reapply for her job, The Guardian says. Earlier this year, the Elliott Management fund had also taken a stake in Glaxo, calling for a leadership change at the company.
Continue to STAT+ to read the full story…
